Top Story Today
A Single Gene Therapy Infusion Could Rewrite Life With a Urea Cycle Disorder
Ultragenyx's gene therapy DTX301 hit its Phase 3 primary endpoint, cutting ammonia levels 18% in patients with OTC deficiency, the most common urea cycle disorder. That number sounds modest until you realize patients were simultaneously eating 13% more protein and taking fewer ammonia-scavenging drugs. Eight of nine patients with elevated ammonia reached normal levels. No approved gene therapy exists for rare metabolic liver diseases, making this a potential first-in-class win for a condition where every meal is a risk calculation.
Why it matters: If the second co-primary endpoint (due H1 2027) confirms patients can ditch their scavenger drugs and loosen dietary restrictions entirely, this becomes more than a clinical milestone. It becomes a proof of concept that AAV gene therapy can tackle rare metabolic diseases, validating Ultragenyx's broader platform ahead of another PDUFA decision in 2026.
Read more →Industry & Strategy
Biotech Turns 50. China Is Coming for the Next 50.
The U.S. biotech industry celebrates its 50th birthday this year, tracing back to two guys and a $500-each bet called Genentech. But the party comes with a sobering reality check: China now runs more clinical trials than the U.S. and holds 30% of global innovative drug candidates versus America's 36%. A national security commission says the window to act is closing fast.
Read more →Devices & Diagnostics
Three Rivals, One Conference, One Target: Millions of Type 2 Diabetics
Insulet, Dexcom, and other device makers showed up to ATTD in Barcelona with the same strategy: chase the massive, undertreated Type 2 diabetes market. Dexcom is defending its premium turf. Insulet is the wildcard, bringing automated insulin pumps to Type 2 patients for the first time with a fully closed-loop system targeting 2028.
Read more →Clinical Trials & Pipeline
Vistagen Cut 20% of Staff. Its Real Gamble Is the Trial It Didn't Cancel.
After its Phase 3 anxiety trial flopped (the placebo worked better than the drug), Vistagen's stock cratered 80%. Now, with $61 million in cash and a burn rate to match, the company fired one in five employees and is betting everything on PALISADE-4, a final Phase 3 trial of its anti-anxiety nasal spray. Results are expected within months. If it misses again, the math gets very ugly.
Read more →